0R15 8520.0 0.0% 0R1E 8203.0 0.0% 0M69 21090.0 67.5139% 0R2V 226.02 9878.8079% 0QYR None None% 0QYP 412.97 -2.8306% 0RUK 2652.0 -9.2402% 0RYA 1554.0 -0.7029% 0RIH 174.55 -1.3563% 0RIH 165.15 -5.3853% 0R1O 198.5 9800.2494% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 165.7358 2.7149%
Last update at 2024-11-21T16:37:00Z
The Craneware Group's 10th Annual Performance Summit a virtual triumph in healthcare excellence
Thu 26 Oct 23, 01:00 PMCraneware (LON:CRW) Is Reinvesting At Lower Rates Of Return
Thu 05 Oct 23, 07:25 AMCraneware's (LON:CRW) Upcoming Dividend Will Be Larger Than Last Year's
Fri 08 Sep 23, 05:01 AMAre Craneware plc (LON:CRW) Investors Paying Above The Intrinsic Value?
Sat 27 May 23, 07:34 AMCraneware (LON:CRW) Might Be Having Difficulty Using Its Capital Effectively
Sun 16 Apr 23, 09:28 AMThe Craneware Group announces it supports and underwrites advocacy group 340B Matters
Mon 27 Mar 23, 12:00 PM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | 13.09M | 13.10M | 13.16M | 19.30M | 18.32M |
| Minority interest | - | - | - | - | - |
| Net income | 9.23M | 9.41M | 12.90M | 16.84M | 14.98M |
| Selling general administrative | 20.38M | 20.38M | 9.30M | 9.98M | 8.72M |
| Selling and marketing expenses | 15.27M | 15.27M | 6.62M | 7.21M | 9.73M |
| Gross profit | 148.44M | 142.37M | 70.20M | 66.97M | 67.01M |
| Reconciled depreciation | 32.16M | 29.40M | 5.24M | 4.67M | 3.53M |
| Ebit | 17.38M | 20.24M | 19.73M | 19.40M | 18.00M |
| Ebitda | 49.54M | 49.64M | 24.97M | 24.06M | 23.94M |
| Depreciation and amortization | 32.16M | 29.40M | 5.24M | 4.67M | 5.93M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 19.23M | 18.13M | 13.24M | 19.21M | 18.00M |
| Other operating expenses | 156.85M | 145.11M | 55.80M | 52.27M | 52.16M |
| Interest expense | 6.36M | 5.03M | 0.08M | 0.09M | 2.09M |
| Tax provision | 3.85M | 3.69M | 0.26M | 2.47M | 3.34M |
| Interest income | 0.21M | 0.00100M | 0.00100M | 0.19M | 0.32M |
| Net interest income | -6.14300M | -5.03000M | -0.07500M | 0.10M | 0.32M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 3.85M | 3.69M | 0.26M | 2.47M | 3.34M |
| Total revenue | 174.02M | 165.54M | 75.58M | 71.49M | 71.40M |
| Total operating expenses | 131.28M | 121.93M | 50.43M | 47.76M | 47.76M |
| Cost of revenue | 25.58M | 23.18M | 5.37M | 4.52M | 4.39M |
| Total other income expense net | -6.65300M | -7.13600M | -6.56200M | 0.10M | 0.32M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 9.23M | 9.41M | 12.90M | 16.84M | 14.98M |
| Net income applicable to common shares | 9.23M | 9.41M | 12.90M | 16.84M | 14.98M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 576.98M | 568.79M | 311.60M | 115.76M | 106.30M |
| Intangible assets | 216.56M | 230.69M | 31.92M | 25.59M | 19.25M |
| Earning assets | - | - | - | - | - |
| Other current assets | 41.25M | 41.25M | 19.43M | 21.00M | 18.79M |
| Total liab | 249.13M | 235.77M | 51.32M | 47.36M | 46.47M |
| Total stockholder equity | 327.84M | 333.02M | 260.28M | 68.39M | 59.84M |
| Deferred long term liab | - | 0.03M | 1.69M | - | - |
| Other current liab | 0.14M | 0.02M | 0.43M | 44.63M | 38.93M |
| Common stock | 0.66M | 0.66M | 0.62M | 0.54M | 0.54M |
| Capital stock | 0.66M | 0.66M | 0.62M | 0.54M | 0.54M |
| Retained earnings | 39.88M | 42.24M | 46.83M | 42.60M | 35.72M |
| Other liab | 44.45M | 48.17M | 0.76M | - | - |
| Good will | 235.24M | 237.65M | 11.19M | 11.19M | 11.19M |
| Other assets | 2.76M | 3.23M | 10.89M | 6.32M | 8.19M |
| Cash | 78.54M | 47.16M | 235.62M | 47.85M | 47.61M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 127.38M | 82.51M | 49.41M | 45.35M | 46.47M |
| Current deferred revenue | 113.85M | 58.70M | 32.19M | -7.62100M | - |
| Net debt | 8.15M | 65.93M | -234.46900M | -45.83400M | -47.61100M |
| Short term debt | 9.39M | 8.00M | 1.05M | 0.95M | - |
| Short long term debt | 8.00M | 8.00M | - | - | - |
| Short long term debt total | 86.69M | 113.08M | 1.15M | 2.02M | - |
| Other stockholder equity | -40.54400M | -42.89500M | -47.45200M | -43.14100M | 23.58M |
| Property plant equipment | 8.46M | 8.82M | 2.55M | 3.80M | 1.27M |
| Total current assets | 113.96M | 88.41M | 255.05M | 68.85M | 66.40M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -123.95200M | -135.31100M | 217.17M | 31.61M | 29.40M |
| Short term investments | - | - | - | - | - |
| Net receivables | 24.17M | 35.31M | 17.04M | 18.95M | 16.86M |
| Long term debt | 75.03M | 103.59M | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 4.00M | 15.79M | 15.74M | 7.39M | 7.53M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -4.80200M | -3.31300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.62M | 0.54M | 0.54M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -460.25700M | 3.23M | -45.66200M | -40.58100M | 4.95M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 463.01M | 480.39M | 56.55M | 46.90M | 39.90M |
| Capital lease obligations | 3.66M | 1.50M | 1.15M | 2.96M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -15.33700M | -307.32000M | -10.32500M | -9.70900M | -10.43400M |
| Change to liabilities | -5.46200M | -13.50000M | 4.20M | -0.87200M | -1.79300M |
| Total cashflows from investing activities | -15.33700M | -307.32000M | -10.32500M | -9.70900M | -10.43400M |
| Net borrowings | -30.55200M | 109.97M | -0.96400M | -1.00300M | -1.00300M |
| Total cash from financing activities | -53.28200M | 91.90M | 174.55M | -10.72100M | -8.25100M |
| Change to operating activities | 50.55M | 50.55M | 50.55M | 50.55M | - |
| Net income | 13.09M | 13.10M | 13.16M | 19.30M | 18.32M |
| Change in cash | 31.38M | -188.46000M | 187.77M | 0.24M | -5.22200M |
| Begin period cash flow | 47.16M | 235.62M | 47.85M | 47.61M | 52.83M |
| End period cash flow | 78.54M | 47.16M | 235.62M | 47.85M | 47.61M |
| Total cash from operating activities | 98.75M | 26.96M | 23.54M | 20.67M | 13.46M |
| Issuance of capital stock | -0.04100M | 1.49M | 187.33M | 0.61M | 0.25M |
| Depreciation | 32.16M | 29.40M | 5.24M | 4.67M | 3.53M |
| Other cashflows from investing activities | 0.21M | 0.00100M | 0.00100M | 0.00100M | 0.00100M |
| Dividends paid | 12.12M | 12.98M | 9.70M | 9.08M | 8.50M |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 1.12M | -3.20300M | 2.03M | -1.18300M | -5.95700M |
| Sale purchase of stock | -3.81500M | -1.72600M | -0.42200M | -1.25500M | 0.25M |
| Other cashflows from financing activities | -9.30700M | 116.09M | 184.25M | 2.15M | -10.43400M |
| Change to netincome | 11.15M | 4.85M | -0.83400M | 1.22M | 2.70M |
| Capital expenditures | 15.55M | 14.03M | 10.33M | 9.71M | 10.43M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 46.20M | -16.70200M | 6.22M | -2.05500M | -7.75000M |
| Stock based compensation | 2.99M | 2.12M | 2.14M | 1.32M | 1.30M |
| Other non cash items | 6.14M | 5.03M | 0.07M | -0.09800M | -0.31800M |
| Free cash flow | 83.20M | 12.93M | 13.21M | 10.96M | 3.03M |
Sector: Healthcare Industry: Health Information Services
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRW Craneware Plc |
10.00 0.45% | 2220.00 | 85.71 | 26.53 | 3.65 | 2.44 | 3.65 | 12.32 |
| INHC Induction Healthcare Group PLC |
- -% | 9.00 | - | 21.51 | 1.76 | 0.96 | 1.48 | -1.6421 |
| RENX Renalytix AI plc |
- -% | 7.75 | - | - | 6.44 | 8.06 | 3.81 | -0.2835 |
| COG Cambridge Cognition Holdings Plc |
0.70 2.53% | 28.40 | - | 238.10 | 1.42 | 18.04 | 0.76 | -2.6598 |
| FDBK Feedback PLC |
- -% | 20.50 | - | - | 9.56 | 0.89 | 2.29 | -0.8995 |
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors. It also offers Trisus Decision Support; Trisus Labor Productivity; Trisus Medication Analytic solutions; and Trisus supplies assistant solutions. In addition, the company provides Sentinel, a drug tracking solution; Sentrex, a SaaS-based solution that helps covered entities expand medication access; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, it offers appeal, professional, and pharmacy professional services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
1 Tanfield, Edinburgh, United Kingdom, EH3 5DA
| Name | Title | Year Born |
|---|---|---|
| Mr. Keith Neilson | Co-Founder, CEO & Exec. Director | 1969 |
| Mr. Craig Thomas Preston ACA | CFO, Company Sec. & Exec. Director | 1971 |
| Ms. Isabel Urquhart | Chief People Officer & Director | 1968 |
| Mr. Abhilesh Gandhi | Group Chief Technology Officer | NA |
| Mr. Derek William Paterson | Chief Information Officer | 1968 |
| Mr. Eric Carter | Chief Legal Officer | NA |
| Mr. Mark Montgomery | Chief Marketing Officer | NA |
| Mr. Seth Droe | Chief Revenue Officer | NA |
| Ms. Karen Bowden RHIA | Exec. VP of Customer Management | NA |
| Ms. Lidia A. Rodriguez-Hupp | Chief Customer Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...